Sökning: id:"swepub:oai:DiVA.org:umu-213966" >
Cabazitaxel shows a...
Cabazitaxel shows a consistently greater survival benefit compared to mitoxantrone in patients with mCRPC
-
- De Bono, Johann S. (författare)
- Royal Marsden Hospital, Experimental Cancer Medicine, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
-
- Sartor, Oliver (författare)
- Tulane University, New Orleans, LA, United States
-
- Geffriaud-Ricouard, Christine (författare)
- Sanofi, Paris, France
-
visa fler...
-
- Joulain, Florence (författare)
- Sanofi, Paris, France
-
- Widmark, Anders (författare)
- Umeå universitet,Onkologi
-
visa färre...
-
(creator_code:org_t)
- Via Medica, 2014
- 2014
- Engelska.
-
Ingår i: Nowotwory. - : Via Medica. - 0029-540X. ; 64:1, s. 1-6
- Relaterad länk:
-
https://doi.org/10.5...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.5...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: This sub analysis of TROPIC study evaluates overall survival (OS) under cabazitaxel in patients who had no initial response to docetaxel (D ) and discontinued D for disease progression and those who initially responded to D but experienced disease progression <3 months since last D dose. These patients are believed unlikely to benefit from D re-treatment and need new treatment options such as cabazitaxel.Methods: Of the 755 patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TROPIC study, 362 (47.9%) had no initial response to D and discontinued it for disease progression, 155 (20.5%) had an initial response to D therapy according to investigator judgment but progressed <3 months since last D dose and 238 (31.5%) did not belong to these two subgroups. All patients were randomized to receive cabazitaxel 25 mg/m2 or mitoxantrone 12 mg/m2 both every 3 weeks and prednisone 10 mg per os daily.Results: Median OS with cabazitaxel was consistently longer than with mitoxantrone in all subgroups. The highest survival benefit versus mitoxantrone was observed for patients who initially responded to D and then progressed <3 months since last D dose (median OS 15.7 versus 11.6 months, Hazard ratio (HR) 0.52 [95% CI 0.35-0.76]). Median PFS was also significantly improved in the latter subgroup compared to mitoxantrone (2.6 versus 1.4 months, HR 0.66 [0.48-0.91]).Conclusion: Cabazitaxel plus prednisone consistently shows a greater survival benefit compared to mitoxantrone plus prednisone whatever the subgroup considered, including responders to first-line D who progressed <3 months since last D and pts without initial response to D who discontinued it for disease progression.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- Cabazitaxel
- Castration-resistant
- Chemotherapy
- Docetaxel resistance
- Prostate cancer
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas